EGFR and neoplasm: For instance, kinase-substrate signatures including CDK1, CDK2, CDC7, CHEK2, MELK, CDK7, IKK, PIM1, and CK2A1 were upregulated, while RET, PKCZ, FYN, AXL, SGK1, MKK4, p90RSK, MEK1, ABL1, LCK, EGFR, and EPHA2 were downregulated in tumor compared to non-tumor samples (Supplementary Fig. 3e).